International Psoriasis Council

Advancing Knowledge. Enhancing Care.

Advancing Knowledge. Enhancing Care.

Bristol Myers Squibb Announces the Committee for Medicinal Products for Human Use (CHMP) has Recommended the Approval of Sotyktu (Deucravacitinib) for the Treatment of Adults with Moderate to Severe Plaque Psoriasis

Psoriasis News BMS Blog Graphic

Bristol Myers Squibb (BMS) announced the positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for once-daily Sotyktu (deucravacitinib) as a treatment for adults with moderate to severe plaque psoriasis who are candidates for systemic therapy. The CHMP decision was based on results from the Phase 3 POETYK PSO-1 and POETYK PSO-2 trials and an additional two years of data from the POETYK PSO long-term extension trial. The CHMP recommendation will be reviewed by the European Commission, and if approved, Sotyktu would be the first oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor in the European Union for the treatment of any disease.

bristol myers squibb logo

Categories

Recent Posts

Shining a Spotlight on our 2022 Fellows: Get to Know the Future Leaders in Psoriasis – Albert Duvetorp, MD, PhD

Medical Adherence in Topical Agents in the Context of Psoriasis Patients

Commentary: The Next Era of Opportunity in Psoriasis: Spatial Transcriptomics

Also Read

Press Release

Sotyktu™ (Deucravacitinib) Recommended by the National Institute for Health and Care Excellence (NICE) for use in England as a First-in-class Treatment Option for Moderate to Severe Plaque Psoriasis in Adults

Bristol Myers Squibb (BMS) announced last week that the National Institute for Health and Care Excellence (NICE) has recommended deucravacitinib, a once-daily oral tablet for use on the NHS in England as an option for treating certain adults with moderate to severe plaque psoriasis.

Read More

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.